- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02474901
Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults (QLAIV)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
QLAIV is an intranasal vaccine that works by using 4 different attenuated strains of influenza virus that will replicate in the nose and stimulate an immune response in recipients that should protect them if they are infected with one of those strains of influenza in the future. A couple of studies have shown an increase in duration that the viruses remain in the nose in immunocompromised people. Those studies were done using the trivalent vaccine, so the investigators would like to evaluate the quadrivalent vaccine, and there is still a need for additional data to help understand the duration of shedding. If shedding is prolonged in HIV-infected children and young adults, it would be important to know for contacts of those individuals who are very immunocompromised. Shedding will be measured by looking for influenza RNA in nasopharyngeal swabs taken at baseline, 2-5 days, 7-10 days and 14-21 days after the intranasal immunization.
The live-attenuated influenza vaccines have been shown to have increased effectiveness in children and they stimulate the immune system in a different way than the inactivated influenza vaccines (TIV or QIV). In this study, the investigators will have the opportunity to compare the immunogenicity of QLAIV, measured at baseline and 14-21 days post-vaccination, in HIV-infected and uninfected children, adolescents and young adults. Although prior studies of LAIV in HIV-infected and other immunocompromised children and adults have not shown any increase in serious adverse events, safety will be actively monitored for the first 30-45 days through a study-specific questionnaire administered at each clinic or phone visit and by asking the subjects to keep a diary of side effects. Safety will be monitored passively throughout the course of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80045
- University of Colorado Denver
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 2-25
- Only supposed to get one dose of vaccine for upcoming influenza season
- No viral respiratory symptoms at time of immunization
HIV-infected group: must have:
- HIV-infection documented by 2 tests such as positive serology, positive HIV DNA or positive HIV RNA;
- must thave a CD4>25% or 500, or
- must have CD4>15% or 200 and be on HAART
- Healthy controls: no major medical problems affecting the immune system
Recruited among:
- HIV-unifected clients of the Children's Immunodeficiency Program(CHIP),
- Children's Hospital Colorado Child Health Clinic and Adolescent Clinics.
Exclusion Criteria:
History of:
- reactive airway disease,
- recurrent wheezing, or
- asthma
- Active wheezing at time of immunization
- On any antiviral agents active against influenza (amantadien/rimantadine, zanamavir, oseltamivir) at time of immunization or planned over 21 days of shedding collection
- Receipt of IVIG within 3 months prior to enrollment
- Plan to receive IVIG during the 4 weeks after immunization
- Moderate to severely immunocompromised individual living in the home
- Pregnant
- Breastfeeding
- Plan to start immunosupressive medications or stop HAART over the 4 weeks following immmunization
- Temperature > 100F or 37.8C
- Rhinorrhea or cough not related to allergies at the time of immunization
- History of fungal sinusitis
- History of Guillain-Barre Syndrome
- Current on antibiotics
- Currently taking aspirin
- On an investigational drug at the time of immunization or planned over the 28 days of shedding collection
- On any experimental medication at time of immunization or planned over 21 days of shedding collection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: QLAIV, HIV-infected
QLAIV administered to HIV-infected individuals 2 to 25 yoa
|
Other Names:
|
Active Comparator: QLAIV, HIV-uninfected
QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Shedding for at Least One of the Influenza Strains Included in the QLAIV in the First 21 Days After Vaccine Administration Days in HIV-positive and Control Groups.
Time Frame: 21 days
|
Measure PCR positivity for any of the influenza subtypes included in QLAIV between baseline (day 0) and the last study visit at 14-21 days after vaccine.
Compare number of participants with PCR positivity for any of the vaccine-strain influenza virus strains in each patient group.
|
21 days
|
Number of Participants With Shedding for at Least One of the Influenza Strains Included in the QLAIV Vaccine at Each of the 4 Study Visits, Days 0 (Baseline), 2-5, 7-10, and 14-21 in HIV-positive and Control Groups.
Time Frame: day 0-21 post-vaccine
|
Measure PCR positivity for any of the influenza subtypes included in QLAIV at visit 1 (day 0), visit 2 (days 2-5), visit 3 (days 7-10) and visit 4 (days 14-21).
Compare number of participants with shedding for any subtype in each patient group.
(The study was powered based on the 7-10 day data.)
|
day 0-21 post-vaccine
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events Within 14 Days After Vaccination
Time Frame: 14 days after vaccination for AEs; up to 30 days for unscheduled visits
|
The investigators will compare the number of adverse events (AE) reported by AE category within 14 days after vaccination as reported by each participant.
Data will reflect whether a participant ever reported the AE, and not the number of times the AE was reported.
|
14 days after vaccination for AEs; up to 30 days for unscheduled visits
|
Number of Participants Reaching Seroprotection (HAI ≥ 40) Within the HIV-positive and Control Groups.
Time Frame: 14-21 days
|
The investigators will measure hemagglutinin inhibition (HAI) on blood samples #2 (14-21 days after vaccination) for all participants.
The investigators will also compare the number of participants reaching HAI ≥ 40 for each virus sub-type contained in the vaccine.
|
14-21 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With PCR-diagnosed Influenza and Clinically-diagnosed Influenza Like Illness.
Time Frame: up to 11 months post-vaccination
|
Compare numbers of participants with influenza diagnosed by PCR and with clinically-diagnosed influenza between the two groups.
Data was taken from Influenza Infection Questionnaires #1 and #2.
The last questionnaire (#2) was administered between May 15 and June 10, 2014 (after the vaccine).
Data is reported as PCR-confirmed influenza and clinically-diagnosed influenza (subject told had influenza without confirmatory testing).
|
up to 11 months post-vaccination
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Adriana Weinberg, MD, University of Colorado, Denver
- Study Chair: Myron Levin, MD, University of Colorado, Denver
- Study Director: Donna Curtis, MD,MPH, University of Colorado, Denver
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- 13-1752
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus (HIV)
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
RTI InternationalCenters for Disease Control and PreventionCompletedHuman Immunodeficiency Virus (HIV) PositiveUnited States
-
Bristol-Myers SquibbCompleted
-
Janssen-Cilag International NVCompletedHuman Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) VirusFrance, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
-
Merck Sharp & Dohme LLCRecruitingHuman Immunodeficiency Virus (HIV) InfectionUnited States, Mexico, Russian Federation, South Africa, Thailand
-
Janssen Inc.CompletedHuman Immunodeficiency Virus (HIV)Canada
-
Auritec PharmaceuticalsEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHuman Immunodeficiency Virus (HIV) ProphylaxisUnited States
-
Columbia UniversityNational Institute of Allergy and Infectious Diseases (NIAID); New York University and other collaboratorsCompletedHIV (Human Immunodeficiency Virus)Swaziland
-
Columbia UniversityMinistry of Health, SwazilandCompleted
Clinical Trials on Quadrivalent Live Attenuated Influenza Vaccine
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes...CompletedInfluenzaUnited States
-
Changchun BCHT Biotechnology Co.He Bei province Center for Disease control and preventionNot yet recruitingInfluenza PreventionChina
-
Changchun BCHT Biotechnology Co.He Bei province Center for Disease control and preventionRecruitingInfluenza PreventionChina
-
National Center for Occupational Health and Infection...US Department of Veterans AffairsTerminated
-
University of Alabama at BirminghamActive, not recruiting
-
Changchun BCHT Biotechnology Co.National Institutes for Food and Drug Control, China; Simoon Record Pharma... and other collaboratorsCompleted
-
Emory UniversityDefense Advanced Research Projects AgencyRecruitingVaccine ResponseUnited States
-
Imperial College LondonPublic Health EnglandCompletedInfluenza VaccinesUnited Kingdom
-
PATHJohns Hopkins University; Bill and Melinda Gates Foundation; Centers for Disease... and other collaboratorsCompleted
-
Imperial College Healthcare NHS TrustCompletedInfluenza | Vaccine Virus SheddingUnited Kingdom